34039 Maintenance of skin clearance in a long-term open-label study of fixed-combination halobetasol propionate and tazarotene lotion for psoriasis in participants with prior use of topical treatments
Gold LS, Alonso-Llamazares J, and Zeichner J. 34039 Maintenance of skin clearance in a long-term open-label study of fixed-combination halobetasol propionate and tazarotene lotion for psoriasis in participants with prior use of topical treatments. J Am Acad Dermatol 2022; 87(3):AB79.
J Am Acad Dermatol
Background: Most patients with psoriasis are dissatisfied with their current treatment, primarily because of limited effectiveness. This post hoc subgroup analysis evaluated long-term efficacy and safety of fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) in participants with use of topical corticosteroid (TCS; 137/550 [24.9%]) or other antipsoriatic topical medications (51/550 [9.3%]) before entry in an open-label study of HP/TAZ (NCT02462083).
Methods: Participants in the open-label study received HP/TAZ once daily. At week 8, participants who achieved treatment success (investigator’s global assessment [IGA] score of 0 or 1) stopped treatment and were reevaluated monthly through 52 weeks; those who did not achieve treatment success continued HP/TAZ. Twenty-four continuous weeks of treatment were allowed if participants achieved ≥1-grade improvement in IGA from baseline at week 12, with monthly reevaluation. If at any point the condition intensified to IGA ≥2, HP/TAZ was resumed, otherwise, HP/TAZ was discontinued.
Results: From weeks 8 to 52, similar treatment success rates were achieved by participants with prior use of TCS (range, 20.0%-40.0%) or other topicals (range, 21.1%-53.8%). Mean affected body surface area at baseline was 5.7% and 5.5%, respectively, and decreased to 3.8% and 2.4%, respectively, at week 52. Percentage of participants who maintained disease control for 29 to 85 days after HP/TAZ cessation was comparable. Rates of adverse events were similar between groups.
Conclusions: Regardless of the type of previous topical therapy, participants with prior use of topical medications maintained skin clearance with HP/TAZ over 52 weeks.